Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03015532 · ClinicalTrials.gov registry record · Phase 2

Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia

A Phase 2 study of Postoperative Pain, sponsored by Heron Therapeutics.

Completed
Registry status
Phase 2
Development phase
285
Enrollment target
20
Study locations

NCT03015532: Completed Phase 2 study of Postoperative Pain, sponsored by Heron Therapeutics.

NCT03015532 is a Phase 2 study of Postoperative Pain that has completed, run by Heron Therapeutics. The registered enrollment target is 285 participants, above the 229-participant average among 120 other Postoperative Pain trials with a reported enrollment target (24% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03015532, a Phase 2 study of Postoperative Pain, has completed, sponsored by Heron Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
285 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2b, randomized, double-blind, saline placebo- and active-controlled, multicenter study in subjects undergoing primary unilateral total knee arthroplasty (TKA) to evaluate the analgesic efficacy, safety, and pharmacokinetics (PK) of HTX-011 administered via infiltration to the surgical site.

Primary Outcome

Pain intensity is assessed at rest using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-48 is 0-480.

Conditions Studied

Interventions

  • DRUG Saline Placebo
  • DRUG Ropivacaine
  • DRUG HTX-011
  • DRUG Bupivicaine HCl

Study Locations (20)

Texas

  • - Bellaire
  • - Houston
  • - Houston
  • - Houston
  • - Plano

Florida

  • - Miami
  • - Miami
  • - Miami
  • - Tamarac

California

  • - La Jolla
  • - Riverside
  • - San Diego

Ohio

  • - Columbus
  • - Columbus
  • - Dayton

Alabama

  • - Mobile
  • - Sheffield

Arizona

  • - Phoenix
  • - Phoenix

Nevada

  • - Las Vegas

Trial Details

FieldValue
Enrollment Target 285 participants
Start Date 2017-01-13
Est. Completion 2018-05-16
Phase Phase 2
Heron Therapeutics

23 total trials

What the finished NCT03015532 record still lists

NCT03015532 is an interventional study that assigns participants to a tested intervention. The registered 285 participants enrollment target is mid-sized for trials with a published cap, above the 229-participant average among 120 other Postoperative Pain trials with a reported enrollment target (24% higher).

The record links to 1 condition, with Postoperative Pain appearing as the primary indexed condition, and to 4 interventions - of which Saline Placebo is the first listed.

NCT03015532 names 20 study sites across 7 states, led by Texas, Florida, California.

Frequently Asked Questions

What is clinical trial NCT03015532 about?

NCT03015532 is a clinical study titled "Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia". This is a Phase 2b, randomized, double-blind, saline placebo- and active-controlled, multicenter study in subjects undergoing primary unilateral total knee arthroplasty (TKA) to evaluate the analgesic efficacy, safety, and pharmacokinetics (PK) of HTX-011 administered via infiltration to the surgica...

What is the current status of trial NCT03015532?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 285 participants. The study started on 2017-01-13. Estimated completion is 2018-05-16.

What conditions does trial NCT03015532 study?

This clinical trial studies the following conditions: Postoperative Pain.

What interventions are being tested in trial NCT03015532?

The interventions under investigation include: Saline Placebo (DRUG), Ropivacaine (DRUG), HTX-011 (DRUG), Bupivicaine HCl (DRUG).

Who is sponsoring clinical trial NCT03015532?

This trial is sponsored by Heron Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03015532 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Postoperative Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03015532's enrollment target sits among peer trials

285 21st of 120 higher than 100 of 120 other Postoperative Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Postoperative Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03412877 · 285 participants · Phase 2

    Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

  • NCT04537936 · 285 participants · NA

    Psychotherapy Intervention for Latinos With Adv Cancer

  • NCT04965675 · 285 participants · Phase 3

    A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

  • NCT05320835 · 285 participants · NA

    A Setting Focus Overdose Prevention Intervention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03015532, the US trial registry maintained by the National Library of Medicine. NCT03015532 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.